Empagliflozin and Cardiac Remodelling in People Without Diabetes
Latest Information Update: 25 Dec 2023
At a glance
- Drugs Empagliflozin (Primary)
- Indications Left ventricular hypertrophy; Myocardial infarction
- Focus Therapeutic Use
- Acronyms EMPA-HEART 2; EMPA-HEART 2 CardioLink-7
Most Recent Events
- 13 Nov 2023 Results determining if Sodium-glucose co-transporter 2 (SGLT2) inhibition with empagliflozin leads to change in blood FABP4 levels and improvement in body composition in patients without diabetes and significant heart failure but with risk factors for adverse cardiac remodeling, presented at the American Heart Association Scientific Sessions 2023
- 06 Mar 2023 Results of sub-study assessing to determine if EMPA modulates RCE in people without T2D who are at elevated cardiovascular (CV) risk, presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation.
- 16 Feb 2023 Status changed from active, no longer recruiting to completed.